AU2017214557A1 - Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof - Google Patents
Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof Download PDFInfo
- Publication number
- AU2017214557A1 AU2017214557A1 AU2017214557A AU2017214557A AU2017214557A1 AU 2017214557 A1 AU2017214557 A1 AU 2017214557A1 AU 2017214557 A AU2017214557 A AU 2017214557A AU 2017214557 A AU2017214557 A AU 2017214557A AU 2017214557 A1 AU2017214557 A1 AU 2017214557A1
- Authority
- AU
- Australia
- Prior art keywords
- dpro
- mleu
- mphe
- phe
- improvement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
A compound of Formula (I), and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.
Description
invention was made with government support under National Institutes of Health grant DP1CA174428. The government has certain rights in the invention.
BACKGROUND OF THE INVENTION FIELD OF THE INVENTION [0003] The present invention relates generally to small molecule compounds and more specifically to the use of such compounds for inhibiting human equilibrative nucleoside transporter 1 (ENT1).
BACKGROUND INFORMATION [0004] Transporter proteins are involved in the cellular uptake of various molecules into and/or through cells. Carrier-mediated transport systems use proteins that are anchored to the cell membrane, typically by a plurality of membrane-spanning domains and function by transporting their substrates via active or passive mechanisms. Carrier-mediated transport systems are involved in the active or non-active, facilitated transport of many important nutrients such as vitamins, sugars, and amino acids. Carrier-mediated transporters are also present in organs such as the liver and kidney, in which the proteins are involved in the excretion or re-absorption of circulating compounds. Polar or hydrophilic compounds typically diffuse poorly across the lipid bilayers that constitute cellular membranes. For many small molecules (e.g., amino acids, di- and tripeptides, monosaccharides, nucleosides and water-soluble vitamins) there exist specific carrier-mediated transporters for active transport of the solute molecules across biological membranes.
[0005] The uptake or release of physiological nucleosides and many of their synthetic analogs by mammalian cells occurs primarily by means of specific carrier-mediated transporters known as nucleoside transporters. Nucleoside transporters have been classified into two categories: (i) equilibrative (facilitated diffusion) and (ii) concentrative (secondary active) sodium-dependent. Two equilibrative transport systems with similar broad substrate
WO 2017/136717
PCT/US2017/016494 specificities have been identified and designated as the es (equilibrative sensitive) and ei (equilibrative insensitive) transporters, on the basis of their sensitivity or insensitivity to inhibition by nitrobenzylthioinosine (NBMPR, 1), respectively.
[0006] Specific transporters are required for the permeation of nucleosides across cell membranes. Among the family of nucleoside transporters the equilibrative nucleoside transporters (ENTs) are the most broadly expressed and four human ENTs have been identified in humans: hENT-1, hENT-2, hENT-3 and hENT-4. The most thoroughly characterized are hENT-1 and hENT-2 which are cell surface proteins and are broadly selective for both purine and pyrimidine nucleosides. They can be distinguished from each other by their sensitivities to inhibition by nitrobenzylmercaptopurine riboside (NBMPR). ENT1 is potently inhibited by nanomolar concentrations of NBMPR and is therefore also called a NBMPR sensitive equilibrative nucleoside transport protein. ENT2 is insensitive to nanomolar concentrations of NBMPR, but can be inhibited by higher (micromolar) concentrations of NBMPR and is therefore also referred to as a NBMPR insensitive equilibrative nucleoside transport protein (iENTP) (see Griffith et al., Biochim. Bioph. Acta 1286:153-181 (1986)).
[0007] Human equilibrative nucleoside transporter 1 (ENT1) is encoded by the SLC29al gene. The gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylmercaptopurine ribonucleoside (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies.
[0008] Adenosine is an endogenous purine nucleoside that is particularly released in pathophysiological conditions like ischemia, inflammation and pain. Under these circumstances it plays an important neuro- and immunomodulatory role. Adenosine administration is analgesic in various nociceptive modalities in humans. Because of the short half-life of adenosine and side-effects caused by its administration, there has been considerable interest in finding ways to reinforce the effects of endogenous adenosine. Inhibition of the ENT1 blocks uptake of adenosine into cells and could enhance its beneficial effects.
WO 2017/136717
PCT/US2017/016494
SUMMARY OF THE INVENTION [0009] In one embodiment, the invention provides compounds that include the following: Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, XII JW95-1, JW95-2, JW95-3, JW95-4, JW95-5, JW95-6, JW95-7, JW95-8, JW95-9, JW95-10, JW95-11, JW95-12, JW95-13, JW95-14, JW95-15, JW95-16, JW95-17, JW95-18, JW95-19, JW95-20, JW95-21, JW95-22, JW95-23, FW95-24, JW95-25, 95-15-1, 95-15-2, 95-15-3, 95-15-4, 95-15-5, 95-15-6, 95-157, 95-15-8, 95-15-9, 95-15-10, 95-15-11, 95-15-12, 95-15-13, 95-15-14, 95-15-15, 95-15-16, 95-15-17, 95-15-18, 95-15-19, 95-15-20, 95-15-21, 95-15-22, 95-15-23, 95-15-13-2, 95-1513-3, 95-15-13-4, 95-15-13-5, 95-15-13-6, 95-15-13-7, 95-15-13-8, 95-15-13-9, 95-15-13-10, 95-15-13-11, 95-15-13-12, 95-15-13-13, 95-15-13-14, 95-15-13-15 and JW95S2Biotin. The compounds are illustrated in the structures provided herein.
[00010] Another embodiment of the present invention is to provide a method of inhibiting human equilibrative nucleoside transporter 1 (ENT1) that includes administering to a subject in need thereof an effective amount of compound listed above.
[00011] Another embodiment of the present invention is to provide a method of increasing adenosine signaling that includes administering to a subject in need thereof an effective amount of a compound listed above.
[00012] Another embodiment of the present invention is to provide a method of increasing adenosine signaling that includes administering to a subject in need thereof an effective amount of a compound listed above. The administering of the aforementioned compound results in one or more of the following effects: increase in antiviral activity, increase in antiparasitic activity, increase in alcohol tolerance, decrease in pain and protection from ischemia, attenuation of epileptic seizure severity, lessening of erectile dysfunction, improvement of liver function, improvement of respiratory disorders, improvement of sepsis, improvement of thrombosis, improvement of hypertension, improvement of inflammatory disorders, improvement of allergies, improvement of cardiac ischemias, improvement of arrhythmias, improvement of Parkinson’s disease, improvement of chronic heart failure, improvement of rheumatoid arthritis, improvement of dry eye disease, improvement of chronic plaque type psoriasis, improvement of chronic neuropathological pain and improvement of sickle cell disease.
[00013] Another embodiment of the present invention is to provide a compound with the following structure:
WO 2017/136717
PCT/US2017/016494
~ OH,. HH-s, SH, CH. B, Gte> or Ofe IndfoMssgy e? ifs mbMcifi.
WfofcreB A JB, X. Y. 2~ C. H, or P «Bar bbBiteib sr b
Wtewsfc,W- OH, BH2, SUM «& <M1« ksSi'ifiikssSSy sr is> rsseifeiaeksb.
Wtefsm A, X, ϊ 2 - ©Bsy iW -- 0-2), C, B, S. whanmr ajs^o^fe. bCiHifeiW «<Γ Ιίΐ SSFi’bSiJHfei.
Rj-Ry H, irssAfjiL sAiyt Hs;>fopyt pbsoytOH, HH2. SB;, CH, bABkbsXy orb sokAiii-Ksfcfi, qrofsyt fespropyb rAsorsyt OH.. AH, CH, MHiHeHiy or bcoerfeis'Sfoofs,
R4 ^ OK. HH?. SB. CN. H; »<s ~ OH, HH.j. SB, GH, H
Η-is - OH NB:, SB, GH, H Rts,-OH, HB2. SB, CH, H
The forbA foefoesssh ihe «tess foeahsiA R,s sod B,g cars foe «Hher a siagH er a ctafofe toriS b either £ ft? ,2 o»rbgeftHift?i.
wherein residues 1-4 can be any amino acid building block listed in below or its modified version
WO 2017/136717
PCT/US2017/016494
FmffisHH IL .........
Fssw OK a
Ms
X_,
Ύ* OH
Ύ
OH
O
FAseHH. JL
...........'·'·'· OH
OH
ChA i- ύκχΗΗ . JL „..
····· OH
Γ?;>λίί:ΗΗ.
o
Ηύι-ϊϊΗΗ „ JL
X 'OH '· 'X «AA
AW
F «·ΧΑί s X γ oh
Ί
S-iRiScX A X>
OH
I °
FwX , .A gH.
i O
1a
OH ssAHs
Η·ν:«Χ
OH
FsacssH
OH xX
X «XX
V..
X?J Α» .;
%O ,φ, iXssSs· «Ash
O
OH i
ftw$ AL ' ¥
FfS'xi X
OH bssAsh
OH c
«AFX
FwsH^Aas “vA «X [00014] Another embodiment of the present invention is to use the foregoing compound in the methods discussed above.
[00015] Other aspects and advantages of the invention will be apparent from the following description and the appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS [00016] Figure 1. RapADOcin inhibits 3H-Adenosine uptake by specifically inhibiting hENTl.
[00017] Figure 2. Rapadocin inhibits 3H-Thymidine uptake in Human Umbilical Vein Endothelial Cells (HUVEC).
[00018] Figure 3. RapADOcin’s uptake inhibition is antagonized by FKBP12-binders Rapamycin and FK506.
WO 2017/136717
PCT/US2017/016494 [00019] Figure 4. 5 RapADOcin inhibits platelet aggregation in human blood when activated by ADP.
[00020] Figure 5. RapADOcin protects against kidney ischemia reperfusion injury in a mouse model.
DETAILED DESCRIPTION OF THE INVENTION [00021] Other aspects and advantages of the invention will be apparent from the following description. Rapadocin Formula I (stylized as RapADOcin or also named JW95) is a synthetic macrocyclic small molecule. Rapadocin specifically inhibits the human equilibrative nucleoside transporter 1 (hENTl or SLC29al) with high potency.
WO 2017/136717
PCT/US2017/016494
[00022] Rapadocin has been shown to be safely tolerated in animals via a kidney ischemia model. Rapadocin is a synthetic macrocycle composed of two ‘domains’- a FKBD (FKBP12 binding domain) and a peptide domain. The FKBD can tolerate modifications at the dimethoxy phenyl region, notably to a dihydroxy phenyl analog. The peptidic fragment can tolerate a range of modifications with varying effects on ENT1 inhibition. Notably, the peptidic fragment can tolerate a few important modifications on the N-methyl phenylalanine residue.
[00023] The compound of Formula I is soluble up to 10 μΜ in aqueous solutions and has been shown to resist degradation over 5 days in cell culture media (37°C, 10% Fetal Bovine Serum).
[00024] Two different families of nucleoside transporters (NTs) have been characterized: equilibrative nucleoside transporters and concentrative nucleoside transporters. Equilibrative nucleoside transporters or ENTs refer to transporters that translocate substrate down the substrate's concentration gradient via passive transport or facilitated diffusion. ENT activity does not require a sodium ion (or other ion) gradient and are therefore termed Na+independent transporters. ENTs are categorized into one of two subtypes based on sensitivity to inhibition by nitrobenzylmercaptopurine riboside (NBMBR).
[00025] Four members of the ENT family have been cloned and are termed ENT1, ENT2, ENT3, and ENT4. All 4 transport adenosine but differ from each other with respect to their ability to transport other nucleosides or nucleobases. ENT1 is an es subtype transporter. Exemplary polynucleotide sequences encoding human ENT1 include GenBank Accession No. U81375 and GenBank Accession No. AAC51103.1 represents the corresponding amino
WO 2017/136717
PCT/US2017/016494 acid sequence. ENT1 is ubiquitously expressed in human and rodent tissues, although expression levels vary between tissues. ENT1 is known to transport a wide range of purine and pyrimidine nucleosides.
[00026] ENT2 is an ei subtype transporter. Exemplary polynucleotide sequences encoding human ENT2 include GenBank Accession No. AF029358 and GenBank Accession No. AAC39526 represents the corresponding amino acid sequence. ENT2 is expressed in a wide range of human and rodent tissues, including vascular endothelium, heart, brain, placenta, thymus, pancreas, prostate, kidney, and muscle, skeletal muscle, cardiac muscle, blood, skin, and ENT2-expressing cancer cells. ENT2-expressing cancer cells include, for example, certain renal tumor cells, breast tumor cells, prostate cancer cells, colon cancer cells, stomach cancer cells, leukemia cells, lung cancer cells, and ovarian cancer cells. Other types of ENT-2 expressing cancer cells are known in the art; (see e.g., Lu X et al., Journal of Experimental Therapeutics and Oncology 2:200-212, 2002, and Pennycooke M et al., Biochemical and Biophysical Research Communications 208, 951-959, 2001). ENT2 exhibits high expression levels in skeletal muscle. ENT2 is also expressed in the membrane of organelles such as the nucleus. ENT2 is known to transport a wide range of purine and pyrimidine nucleosides and nucleobases.
[00027] It is expected that inhibition of hENTl by Rapadocin and its analogs will increase the extracellular concentrations of adenosine, thereby enhancing its signaling via adenosine receptors. Adenosine receptor agonists have been sought as treatments for multiple diseases. It is expected that Rapadocin will have similar activity as adenosine receptor agonists.
[00028] As used herein, a therapeutically effective amount of a compound, is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a discernible inhibition of the ENT1 transporters. The exact dosage and frequency of administration depends on the particular compound of the invention used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as the other medication, the patient may be taking, as is well known to those skilled in the art. Furthermore, said therapeutically effective amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines. The invention compounds may be used for the manufacture of a medicine for treatment of a condition or a
WO 2017/136717
PCT/US2017/016494 disease mediated by equilibrative nucleoside transporter ENT1 activity, in particular equilibrative nucleoside transporter ENT 1 inhibitory activity.
[00029] Equilibrative nucleoside transporter ENT1 mediated conditions or disorders may include but are not limited to acute and chronic pain conditions including inflammatory pain, neuropathic pain, cancer pain, cardioprotection, cerebroprotection, traumatic brain injury (TBI), myeloprotection, neuroprotection, chronic pressure skin ulcers, wound healing, ischemia, anticonvulsant, organ transplant (organ preservation, like cardioplegia), sleep disorders, pancreatitis, glomerulonephritis, and antithrombotic (anti-platelet).
[00030] Nucleoside transport pathways refer to systems of one or more transport proteins that effect the transport of a substrate across one or more biological membranes. For example, a nucleoside transport pathway may mediate the step-wise transport of a substrate across the plasma membrane followed by the transport of the substrate across the membrane of an intracellular organelle. The transport proteins or nucleoside transporters responsible for such a step-wise translocation of a substrate across two biological membranes may be the same type of nucleoside transporter or may be of different types. In certain embodiments, the nucleoside transporter may be an equilibrative nucleoside transporter. In other embodiments, the nucleoside transporter may be a concentrative nucleoside transporter.
[00031] A transport protein or transporter is a protein that has a direct or indirect role in transporting a molecule across a membrane. The term includes, for example, membranebound proteins that recognize a substrate and effects its entry into, or exit from a cell by a carrier-mediated transporter or by receptor-mediated transport. Transporters may be present on plasma membranes or the membranes of intracellular organelles. Thus, transporters facilitate the transport of molecules into the cytoplasm or into an intracellular organelle. [00032] The term nucleoside refers to a purine or pyrimidine base that is covalently linked to a 5-carbon sugar (i.e., pentose). When the sugar is ribose, the nucleoside is a ribonucleoside; when it is 2-deoxyribose, the nucleoside is a deoxyribonucleoside. Exemplary nucleosides include cytidine, uridine, adenosine, guanosine, and thymidine, and the corresponding deoxyribonucleosides, which form the basis of the nucleotides that form DNA and RNA.
[00033] The term nucleoside analog as used herein refers to a nucleoside in which the base moiety, the sugar moiety or both has been modified. Such analogs are generally synthetic and mimic natural nucleosides so that they may take the place of a nucleoside in cellular functions. For example, nucleosides may be incorporated into DNA or RNA in place
WO 2017/136717
PCT/US2017/016494 of the natural corresponding nucleoside. Certain nucleoside analogs so incorporated can, for example, prevent further elongation of the nucleic acid chain during synthesis. Many nucleoside analogs have anti-viral or anti-cancer properties. Examples of nucleoside analogs include inosine, deoxyadenosine analogs such as didanosine (2',3'-dideoxyinosine, ddl) and vidarabine (9-O-D-ribofuranosyladenine), deoxycytidine analogs such as cytarabine (cytosine arabinoside, emtricitabine, lamivudine (2',3'-dideoxy-3'-thiacytidine, 3TC), and zalcitabine (2'-3'-dideoxycytidine, ddC), deoxyguanosine analogs such as abacavir, (deoxy-)thymidine analogs such as stavudine (2'-3'-didehydro-2'-3'-dideoxythymidine, d4T) and zidovudine (azidothymidine, or AZT), and deoxyuridine analogs such as idoxuridine and trifluridine. [00034] The term pharmaceutically acceptable salts refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention, e.g., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.
[00035] In order to prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with at least one pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for oral administration, rectal administration, percutaneous administration or parenteral injection.
EXAMPLE 1
RapADOcin inhibits nucleoside uptake [00036] Rapadocin potently and specifically inhibits nucleoside uptake by human equilibrative nucleoside uptake transporter 1 (hENTl) over hENT2, the two most predominant eqilibrative nucleoside transporters (Fig. 1). Rapadocin inhibits nucleoside
WO 2017/136717
PCT/US2017/016494 [00037] uptake in at least seven cell lines and is predicted to inhibit nucleoside uptake in all human cell lines (see e.g., Fig. 2 and Table 1).
HUVEC 293T | RKO | A549 | HeLa | MDA ' MB-231 | |
EC50 | 6.4nM 5.0nM 11.4nM | 6.3nM | 16.3nM | 9.0nM 41.1nM | |
Table 1 | 3H-Thymidine uptake in various cell lines | ||||
Rapafucin analogs | |||||
Peptide | |||||
Analog | Residue 1 | Residue 2 | Residue 3 | Residue 4 | EC50 3H-Tymidine uptake |
JW95-1 | mGly | dPro | mGly | Phe | >luM |
JW95-2 | mAla | dPro | mGly | Phe | >luM |
JW95-3 | mLeu | dPro | mGly | Phe | >luM |
JW95-4 | mSer | dPro | mGly | Phe | 1228 |
JW95-5 | mPhe | dPro | mGly | Phe | 440 |
JW95-6 | mGly | dPro | mAla | Phe | >luM |
JW95-7 | mAla | dPro | mAla | Phe | >luM |
JW95-8 | mLeu | dPro | mAla | Phe | >luM |
JW95-9 | mSer | dPro | mAla | Phe | >luM |
JW95-10 | mPhe | dPro | mAla | Phe | >luM |
JW95-11 | mGly | dPro | mLeu | Phe | >luM |
JW95-12 | mAla | dPro | mLeu | Phe | >luM |
JW95-13 | mLeu | dPro | mLeu | Phe | 787 |
JW95-14 | mSer | dPro | mLeu | Phe | 725 |
JW95-15 | mPhe | dPro | mLeu | Phe | 377 |
JW95-16 | mGly | dPro | mSer | Phe | >luM |
JW95-17 | mAla | dPro | mSer | Phe | >luM |
JW95-18 | mLeu | dPro | mSer | Phe | >luM |
JW95-19 | mSer | dPro | mSer | Phe | >luM |
JW95-20 | mPhe | dPro | mSer | Phe | >luM |
JW95-21 | mGly | dPro | mPhe | Phe | >luM |
JW95-22 | mAla | dPro | mPhe | Phe | 731 |
JW95-23 | mLeu | dPro | mPhe | Phe | >luM |
JW95-24 | mSer | dPro | mPhe | Phe | >luM |
WO 2017/136717
PCT/US2017/016494
JW95-25 | mPhe | dPro | mPhe | Phe | >luM |
95-15-1 | mLeu | dPro | mPhe | Phe | 112 |
95-15-2 | mdLeu | dPro | mPhe | Phe | >luM |
95-15-3 | mLeu | dPro | mPhe | dhoPhe | >luM |
95-15-4 | Leu | dPro | mPhe | Phe | >luM |
95-15-5 | mile | dPro | mPhe | Phe | >luM |
95-15-6 | mNle | dPro | mPhe | Phe | >luM |
95-15-7 | mLeu | Pro | mPhe | Phe | >luM |
95-15-8 | mLeu | Gly | mPhe | Phe | >luM |
95-15-9 | mLeu | dPro | mdPhe | Phe | >luM |
95-15-10 | mLeu | dPro | Phe | Phe | 182 |
95-15-11 | mLeu | dPro | mPhe | dPhe | >luM |
95-15-12 | mLeu | dPro | mPhe | hoPhe | >luM |
95-15-13 | mLeu | dPro | mPhe | Phg | 15 |
95-15-14 | mLeu | dPro | mPhe | PheF | >luM |
95-15-15 | mLeu | dPro | mPhe | PheCI | >luM |
95-15-16 | mLeu | dPro | mPhe | Phel | >luM |
95-15-17 | mLeu | dPro | mPhe | Tyr | >luM |
95-15-18 | mLeu | dPro | mPhe | TyrBu | >luM |
95-15-19 | mLeu | dPro | mPhe | PheNO2 | >luM |
95-15-20 | mLeu | dPro | mPhe | mPhe | >luM |
95-15-21 | mLeu | dPro | mPhe | Cha | 112 |
95-15-22 | mLeu | dPro | mPhe | Nal | >luM |
95-15-23 | mLeu | dPro | mPhe | biPhe | >luM |
RapADOcin | mLeu | dPro | mPhe | Phg | 6.16 |
95-15-13-2 | mLeu | dHoPro | mPhe | Phg | 1920 |
95-15-13-3 | mLeu | dPro | Phe | Phg | 64 |
95-15-13-4 | mLeu | dPro | Pyr | Phg | 266 |
95-15-13-5 | mLeu | dPro | hoPhe | Phg | 15 |
95-15-13-6 | mLeu | dPro | Phg | Phg | 261 |
95-15-13-7 | mLeu | dPro | PheF | Phg | 56.7 |
95-15-13-8 | mLeu | dPro | PheCI | Phg | 123 |
95-15-13-9 | mLeu | dPro | Phel | Phg | 62.5 |
95-15-13-10 | mLeu | dPro | Tyr | Phg | 9.64 |
WO 2017/136717
PCT/US2017/016494
95-15-13-11 | mLeu | dPro | TyrOMe | Phg | 32.5 |
95-15-13-12 | mLeu | dPro | PheNO2 | Phg | 130 |
95-15-13-13 | mLeu | dPro | Cha | Phg | 199 |
95-15-13-14 | mLeu | dPro | Nal | Phg | 87.8 |
95-15-13-15 | mLeu | dPro | biPhe | Phg | 194 |
JW95DIOI1 Formula II | mLeu | dPro | mPhe | Phg | 3 |
JW95TyrBiotin Formula III | mLeu | dPro | Tyr(PEG)2Biotin | Phg | 54 |
JW95S2Biotin | mLeu | dPro | mPhe | Phg | >luM |
JW95TyrDiaz Esw^miiIk Ilf | mLeu | dPro | Tyr—Diaz | Phg | 20nM |
Formula IV 1JW95Diol utilizes a modified FKBD where the two methoxy groups are replaced with hydroxyl groups
Table 2 [00038] Table 2 discloses the potency of various Rapadocin analogs.
[00039] Structures of selected Rapadocin analogs are represented as follows:
JW95Dlol
Formula II
WO 2017/136717
PCT/US2017/016494
ΟΜβ
JW9STyrBtoiln Formula ΠΙ
JWSSTyrdiaz Formula IV
WO 2017/136717
PCT/US2017/016494
EXAMPLE 2
Human and Animal Models [00040] Two human and animal models have been studied to show the efficacy of Rapadocin (Figs. 4 and 5). Under several physiological conditions, adenosine is released into the blood where it can act on adenosine receptors. Normally, this adenosine (ADO) is rapidly reabsorbed via ENT1. In the presence of Rapadocin, uptake is inhibited and ADO is able to produce enhanced signaling leading to several potentially beneficial physiological responses. EXAMPLE 3 [00041] Additional compounds that can be used to improve Pharmacokinetics /Pharmacodynamics and solubility of the leads include the following.
WO 2017/136717
PCT/US2017/016494
R i = OH, NH2. SH, H)
Formula VII
η ~ 0-6
R<-R?: individually or in combination, = methyl, ethyl, propyl, isopropyl, phenyl, OH, NHL, SH,
Formula VIII
WO 2017/136717
PCT/US2017/016494
Formula IX
A=B=X=Y=Z= G;
A, Β. X, Y 2 = N, P;
Λ >» ... A l V η. ΑΛ .m X
A = | B ~ | N, | X = Y = | = Z | - H |
X = | 2 - | = N, | Y= A= | = B | ~ H |
X = | *= | = N, | Y = Z = | : B | - H |
X = | Y= | - V · ·* Z- - | -- N A- | B | = H |
x~ | Ύ- | s 7 : | = A=N | B | = H |
Formula X
WO 2017/136717
PCT/US2017/016494
™ methyi, ethyl, atopy!, isopropyl, phenyl, OH, NH , SB.
Formula XI
Formula XII
WO 2017/136717
PCT/US2017/016494
EXAMPLE 4
Scheme 1
Synthetic route for RapADOcin with FKBD 8 ©Me
Cx ©Me
ΜβΟ-e -1.
1,0.
γ NHa
u.
0
V
If o
'NH,
Ms©
MeQ—,.
:0 ©Ma +A.,;\
OR
111
MeG~ v® ί— R ~ H (21)
60?$ steps I—>
\Z xX
OH
OMs
Cl
OMs
MaO.. ,.<C
II
..-X i n........
111,1 «2%
O,, lx O
O ,0
X-' X.1 ,x , W'! o
%A> θ υ^·χ..-Ο·'η--Αχ
Q ,QH °x¥0° ”V δ
[00042] Reaction conditions: i) KOH, H2O/EtOH (1/20), RT, 6h; ii) Pd/C (10%), H2, MeOH, RT, 1.5 h; iii) tert-butyl 2-bromoacetate, K2CO3, DMF/acetone (1/2), RT, 4h; iv) (+)DIPC1, THF, -20°C to RT, 5h; v) FKBD 8, benzoyl chloride, DMAP (5%), NEt3, CH2C12, RT, 4h; vi) TFA (10%), CH2C12, RT, 6h; vii) succinic anhydride, DMAP (5%), CH2C12, RT, 3h; viii) allyl bromide, Cs2CO3, DMF, RT, 2h; ix) Pd(PPh3)4 (10%), N-methylaniline, THF, RT, 6h.
WO 2017/136717
PCT/US2017/016494
EXAMPLE 5 [00043] Compounds that can be used to improve Pharmacokinetics /Pharmacodynamics and solubility are represented by the following generic structure:
A’
WHereb RARs - OR. ?HH. OH OR. H, CAr. tfi Ofe bdRitohy «rb wo&fcsefeso.
sWoab; A .8,. X, V. Z- 0. H, or P ester bcSsHdasiH orb eemi&s&SteR,
R; W - OH, HH2. CH, «. OOs, Ote tetobMahy w hi
WSwste A, >i, Y, iR it ~ OHsY ξ!Ϋ 8-2), O, H S. wfeersw sppfsphsH. fesMteily isr hi oawfeiosta.
^2-¾ H, jneftyl, ebb, propjfS, IsejX’W?. 0¾. CH, Mbssbshy <Ars iXiftAbshbs,
Rs»Ss:iWWl sbA pwA bepswi pHWl OH HH& ®H, CR. bbHsbabi «tin ixasHfobba »s CH, RH2. SH> CH, H;
% - OH. RH j, CH, GH, R,
Η-ΐΐ.ζ;.ι “ H ei M«.·
As OH. CH, CH, H;
- OH. RA 8H,CH, H.
The Herb teiwebs b« mfeens tesifeg H. g srb R,s ess fee bbsi a sbgfe ix a iteabfe Rc?aAb Wser6 or X «marten.
WO 2017/136717
PCT/US2017/016494
Residues 1-4 can be any amino acid building block listed in Table 3 or its modified version.
Fiw»i X
V OH
CX
FsweHH X
OH
FjrsscHH .A ©
FhsosW JL
OH A 'OH c
XA
© o >XgH | © Ί « 'Q'Y | o | G FwsH&L X. I |
Yy'Y ©H | A | T | |
U ' | Y.y | 1 | |
o»a | w | dLs-ii | |
i’X | G | O |
©H
Λ,
QH
F—^γΧ,
l. Λ / k..r, fshsa ©H
ΊΠ
Ύ
X.Y .A F^JyjL talXjl, y' X;OH
ΌΗ
FisssxA i
ύ ssW
FAscH „ X .
--- A
Ό
8sH>>8
OH
A...
Y ?
Assety X.
OH © ,χ.
i ©
Ύ'
OH
JL ' 'x.y Y0t^ yOfgsJs X.
$58^8
OH j O FsfssO «Α \Y
8©A;«
SiHHf
Y
Ί
Table 3. Amino Acid Building Blocks for Residues in the Effector Domain [00044] References 11-15 describe the use of adenosine agonists in the treatment of various diseases. Based upon the information disclosed in these references, one of ordinary skill in the art would recognize that the compounds disclosed in this application could be used to treat these diseases. See e.g., Table 2 of Reference 15 as it relates to the treatment of arrhythmias.
[00045] Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed herein are for illustrative purposes only and various modifications and alterations might be made by
WO 2017/136717
PCT/US2017/016494 those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.
WO 2017/136717
PCT/US2017/016494
REFERENCES
The following references are each relied upon and incorporated herein in their entirety.
1. Passer, B. J. et al. Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication. Cancer Res. IQ, 3890-3895 (2010).
2. Rose, M. & Schiedel, A. C. Nucleoside/nucleobase transporters: drug targets of the future? Future Med. Chem. 1, 303-326 (2009).
3. Melendez, R. I. & Kalivas, P. W. Last call for adenosine transporters. Nat. Neurosci. 7, 795-796 (2004).
4. Choi, D.-S. et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat. Neurosci. 7, 855-861 (2004).
5. Puetz, C. et al. Nitrobenzylthioinosine compounds for relief ofpain. (Google Patents, 2008). at <https://www.google.com/patents/US7358235>
6. Sawynok, J. in Adenosine 343-360 (Springer, 2013). at <http://1 ink.springer.com/chapter/10.1007/978-1 -4614- 3903-5 17>
7. Bauerle, J. D., Grenz, A., Kim, J.-H., Lee, Η. T. & Eltzschig, Η. K. Adenosine Generation and Signaling during Acute Kidney Injury. J. Am. Soc. Nephrol. 22, 14-20 (2011).
8. Grenz, A. et al. The Reno-Vascular A2B Adenosine Receptor Protects the Kidney from Ischemia. PLoSMed. 5, el37 (2008).
9. Grenz, A. et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J. Clin. Invest. 122, 693-710 (2012).
10. Zimmerman, M. A. etal. Equilibrative nucleoside transporter (ENT)-1-dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion. Hepatology 58, 1766-1778 (2013).
11. Mohamadnejad, M. et al. Adenosine inhibits chemotaxis and induces hepatocyte-specific genes in bone marrow mesenchymal stem cells. Hepatology 51(3), 963-73 (2010).
12. Wen, J. etal. Adenosine signaling: good or bad in erectile function? Arterioscler Thromn Vase Biol 32(4), 845-50 (2012).
13. Xu, Z. etal. ENT1 inhibition attenuates epileptic seizure severity via regulation of glutamatergic neurotransmission. Neuromolecular Med. 17(1), 1-11 (2015).
14. Chen, J. eta al. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Disc 12(4), 265-86 (2013).
WO 2017/136717
PCT/US2017/016494
15. Sachdeva, S. et al. Adenosine and its receptors as therapeutic targets: An overview. Saudi Pharmaceutical Journal 21, 245-253 (2013).
16. Griffith et al., Biochim. Bioph. Acta 1286:153-181 (1986).
17. Lu X et al., Journal of Experimental Therapeutics and Oncology 2:200-212, 2002.
18. Pennycooke M et al., Biochemical and Biophysical Research Communications 208, 951959, 2001.
WO 2017/136717
PCT/US2017/016494
Claims (4)
1.0
Fraction Affected
FIGURE 3
ADPIOyM
FIGURE 4
Cottager? 1 pg/m L
WO 2017/136717
PCT/US2017/016494
1/4
FIGURE 1
WO 2017/136717
PCT/US2017/016494
£$-* ^j% _X >*· Pfe© ©
XxH'i X
OH
X jed
Xs?
Fawt<
I 0 CJ j ««fee
0'
LA
X' 'qk :
6. A method of inhibiting human equilibrative nucleoside transporter 1 (ENT1) comprising administering to a subject in need thereof an effective amount of a compound of claim 5, thereby inhibiting ENT1.
7. A method of increasing adenosine signaling comprising administering to a subject in need thereof an effective amount of a compound of claim 5, thereby increasing adenosine signaling.
8. A method of increasing adenosine signaling comprising administering to a subject in need thereof an effective amount of a compound of claim 5, wherein the administering of the compound of claim 5 results in one or more of the effects selected from the group consisting of an increase in antiviral activity, an increase in antiparasitic activity, an increase in alcohol
WO 2017/136717
PCT/US2017/016494 tolerance, a decrease in pain, protection from ischemia, attenuation of epileptic seizure severity, lessening of erectile dysfunction, improvement of liver function, improvement of respiratory disorders, improvement of sepsis, improvement of thrombosis, improvement of hypertension, improvement of inflammatory disorders, improvement of allergies, improvement of cardiac ischemias, improvement of arrhythmias, improvement of Parkinson’s disease, improvement of chronic heart failure, improvement of rheumatoid arthritis, improvement of dry eye disease, improvement of chronic plaque type psoriasis, improvement of chronic neuropathological pain and improvement of sickle cell disease.
WO 2017/136717
PCT/US2017/016494
1. A compound selected from the group consisting of one of the following:
OH
Formula I (JW95, Rapadocin)
OMe
WO 2017/136717
PCT/US2017/016494
Formula VII
WO 2017/136717
PCT/US2017/016494
8. S i taSv coniNpariuT -ttteihv! 0’M propyl laqropys nhenyj OH WH , SH
Formula Vin
Formula IX
A=e=x=yi=z=:C;
A>B, ····.· ii « (v, X “ Y = 2 -H'. X~Z = <¥ = A-B = !··:
Χ = Ϋ = 2 = Κ A= B = H; X- ,-= ;·> A-ί·,. !·=:·:· Formula X
R,:-R4: indiv'tdtiaiSy er in combindtfen, * iwsthyi, Sthjl prapyii ίδβρΙφ/Ι, plwfiyi,
OH NH;, SH.
Formula ΧΪ
WO 2017/136717
PCT/US2017/016494 iX Y=O,NH, S;
L - alkyl palyather or iiftffArs'wih varying chaw length.)
Formula XII
.............................................................................
Seskiuei Residue 2 Rescue 3 ^sdue4
WO 2017/136717
PCT/US2017/016494
Peptide
2/4 o'
3H ~Thym idine incorporation
100
162e-00S •to g[RapAQOcin] (M >
FIGURE 2
WO 2017/136717
PCT/US2017/016494
2 i ?©»
2. A method of inhibiting human equilibrative nucleoside transporter 1 (ENT1) comprising administering to a subject in need thereof an effective amount of a compound of claim 1, thereby inhibiting ENT1.
3/4 • JW 9 5+ R ap a m ycin JW95 + FK506 c
o c
jD
H -10 ©
o
0,2 0,4 0,6 0.8
3. A method of increasing adenosine signaling comprising administering to a subject in need thereof an effective amount of a compound of claim 1, thereby increasing adenosine signaling.
4. A method of increasing adenosine signaling comprising administering to a subject in need thereof an effective amount of a compound of claim 1, wherein the administering of the compound of claim 1 results in one or more of the effects selected from the group consisting
WO 2017/136717
PCT/US2017/016494 of an increase in antiviral activity, an increase in antiparasitic activity, an increase in alcohol tolerance, a decrease in pain, protection from ischemia, attenuation of epileptic seizure severity, lessening of erectile dysfunction, improvement of liver function, improvement of respiratory disorders, improvement of sepsis, improvement of thrombosis, improvement of hypertension, improvement of inflammatory disorders, improvement of allergies, improvement of cardiac ischemias, improvement of arrhythmias, improvement of Parkinson’s disease, improvement of chronic heart failure, improvement of rheumatoid arthritis, improvement of dry eye disease, improvement of chronic plaque type psoriasis, improvement of chronic neuropathological pain and improvement of sickle cell disease.
WO 2017/136717
PCT/US2017/016494
5.
A compound of the following structure:
5 H Resstes
Γ ^R«aites x--..·· N Y o’ 'χ'Υ·'·· n -08
Wtefgsf! R, W - OH, MHa, SH, CH, H. OAo, orC^fe Msvk&s^j; Orbs iSiOibAfsboo.
<
A~e
WhsreAs: A,8, X, Y, 2~ Ο, Η, «r P «Rtef bdHAsrfy <sr stj cansijfrsafei,
W&emin R?W OH. OH5, SH, H.; ΟΑς cfe indMsto^ or in osfofefesta.
Wherein A, X, Y, or 2 ® CHrf {η* ® SY2), Ο, H, S, ssrheraw «wwAY®, tndOtefss?^ of io oosofefesAofr
0·?Ά: Η, rfto s0-,: ppepH, Hopro^A A«:f5y!.;OH, GHj, OH, CH, indMdaAiy «0« cwfeinata,
0,, AA!08tfeA sifcyi, pwA SS0s»M ptesfiA OH, 0% SA CH, ifAGisteW Of in ppsoAosAa,
R^-OR. HHaSH,CH,H.:
0ΐ3 - CH, HHE, CH, CH, H,
Kj;..;s,- Safe i-A - OH, HH2, SH, CH, H;
R..? GH, HH2, OH, C« H.
The Asob WfweAo iht csRsoofs bearing H? $ ami RSs ca^ tee «bteer a eingia or a tofOte b?»A A «Sher E « 2 «w§g«f»ta,· wherein residues 1-4 can be any amino acid building block listed in below or its modified
WO 2017/136717
PCT/US2017/016494 version
OH
FissssHH X
V* OH
Pe®
W) tteSs«i
V
FfiK'cBN ,X.-..., . Vtt
OH ©
Fms«4^^Xw F^kc44^X
X'X
X©
4/4
0,0003
Creatfsiifie (fflg/tfL) p= 0.47 2
FIGURE 5
0.0 5 4
0.594
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291428P | 2016-02-04 | 2016-02-04 | |
US62/291,428 | 2016-02-04 | ||
PCT/US2017/016494 WO2017136717A1 (en) | 2016-02-04 | 2017-02-03 | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2017214557A1 true AU2017214557A1 (en) | 2018-08-16 |
AU2017214557B2 AU2017214557B2 (en) | 2022-05-19 |
Family
ID=59500022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017214557A Active AU2017214557B2 (en) | 2016-02-04 | 2017-02-03 | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (2) | US10774110B2 (en) |
EP (2) | EP3411032B1 (en) |
JP (1) | JP7022069B2 (en) |
CN (2) | CN113999281A (en) |
AU (1) | AU2017214557B2 (en) |
CA (1) | CA3013650A1 (en) |
ES (1) | ES2837484T3 (en) |
MX (2) | MX2018009407A (en) |
WO (1) | WO2017136717A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017214557B2 (en) | 2016-02-04 | 2022-05-19 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
MX2018009408A (en) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutins, novel inhibitors of glut and use thereof. |
TW202126323A (en) | 2019-10-01 | 2021-07-16 | 約翰斯赫普金斯大學 | Rapafucin derivative compounds and methods of use thereof |
AR121777A1 (en) * | 2020-04-07 | 2022-07-06 | iTeos Belgium SA | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCER, AND THE COMBINATION OF THESE WITH ADENOSINE RECEPTOR ANTAGONISTS |
WO2023056910A1 (en) * | 2021-10-06 | 2023-04-13 | iTeos Belgium SA | Processes for preparing a macrocyclic compound having ent1 inhibiting activity |
WO2023059739A1 (en) * | 2021-10-06 | 2023-04-13 | iTeos Belgium SA | Macrocyclic compounds having ent1 inhibiting activity |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5457194A (en) | 1993-03-17 | 1995-10-10 | Abbott Laboratories | Substituted aliphatic amine-containing macrocyclic immunomodulators |
US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
US7056935B2 (en) | 1995-06-07 | 2006-06-06 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
EP1352910A1 (en) | 2002-04-10 | 2003-10-15 | Grünenthal GmbH | New analogs of nitrobenzylthioinosine |
GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
SI1615613T1 (en) | 2003-04-18 | 2010-03-31 | Enanta Pharm Inc | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
US20060003362A1 (en) | 2004-06-04 | 2006-01-05 | Xenoport, Inc. | ENT1 transporters expressed in cancer cells |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
EP2368868A1 (en) | 2005-10-28 | 2011-09-28 | Praecis Pharmaceuticals Inc. | Methods for identifying compounds of interest using encoded libraries |
US20080306098A1 (en) | 2006-11-06 | 2008-12-11 | Mutz Mitchell W | Pharmacokinetics of protease inhibitors and other drugs |
RU2483714C2 (en) | 2007-03-07 | 2013-06-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. | Nanoparticle, containing rapamycin and albumin as anti-cancer agent |
AU2008256644B2 (en) | 2007-05-24 | 2014-07-03 | The United States Government As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
JP2011524413A (en) | 2008-06-17 | 2011-09-01 | バイオチカ テクノロジー リミテッド | Novel compounds and methods for their production |
WO2012075048A2 (en) | 2010-11-30 | 2012-06-07 | The Johns Hopkins University | Hybrid cyclic libraries and screens thereof |
WO2012106702A2 (en) | 2011-02-04 | 2012-08-09 | The General Hospital Corporation | Treatment of leukemia |
EP2607352A1 (en) | 2011-12-22 | 2013-06-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pipecolate-diketoamides for treatment of psychiatric disorders |
KR101733736B1 (en) | 2012-01-06 | 2017-05-10 | 삼성에스디아이 주식회사 | Negative active material for rechargeable lithium battery, method prepareing the same and rechargeable lithium battery including the same |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
EP3007696B1 (en) | 2013-06-14 | 2019-10-16 | The Board of Regents of The University of Texas System | Novel allosteric inhibitors of proteasome and methods of use thereof |
US10533016B2 (en) | 2015-01-09 | 2020-01-14 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
EP4242304A3 (en) | 2015-10-01 | 2024-02-07 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
MX2018009408A (en) * | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutins, novel inhibitors of glut and use thereof. |
US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
MX2018009405A (en) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Synthesis and composition of rapafucin libraries. |
AU2017214557B2 (en) | 2016-02-04 | 2022-05-19 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
PE20181803A1 (en) | 2016-04-22 | 2018-11-19 | Astrazeneca Ab | MACROCYCLIC MCL-1 INHIBITORS TO TREAT CANCER |
WO2018045250A1 (en) | 2016-09-02 | 2018-03-08 | The Johns Hopkins University | Mif inhibitors and methods of use thereof |
UY37900A (en) | 2017-09-26 | 2019-04-30 | Novartis Ag | NEW DERIVATIVES OF RAPAMYCIN |
-
2017
- 2017-02-03 AU AU2017214557A patent/AU2017214557B2/en active Active
- 2017-02-03 JP JP2018540114A patent/JP7022069B2/en active Active
- 2017-02-03 EP EP17748270.0A patent/EP3411032B1/en active Active
- 2017-02-03 MX MX2018009407A patent/MX2018009407A/en unknown
- 2017-02-03 CA CA3013650A patent/CA3013650A1/en not_active Abandoned
- 2017-02-03 ES ES17748270T patent/ES2837484T3/en active Active
- 2017-02-03 WO PCT/US2017/016494 patent/WO2017136717A1/en active Application Filing
- 2017-02-03 EP EP20198397.0A patent/EP3782636A1/en active Pending
- 2017-02-03 CN CN202111210158.8A patent/CN113999281A/en active Pending
- 2017-02-03 US US16/073,746 patent/US10774110B2/en active Active
- 2017-02-03 CN CN201780010178.6A patent/CN108697701B/en active Active
-
2018
- 2018-08-02 MX MX2021002588A patent/MX2021002588A/en unknown
-
2020
- 2020-08-26 US US17/003,940 patent/US11555054B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10774110B2 (en) | 2020-09-15 |
US20200392182A1 (en) | 2020-12-17 |
EP3411032A4 (en) | 2019-08-14 |
EP3411032B1 (en) | 2020-09-30 |
MX2018009407A (en) | 2018-11-09 |
EP3411032A1 (en) | 2018-12-12 |
CA3013650A1 (en) | 2017-08-10 |
EP3782636A1 (en) | 2021-02-24 |
JP7022069B2 (en) | 2022-02-17 |
CN108697701A (en) | 2018-10-23 |
AU2017214557B2 (en) | 2022-05-19 |
JP2019508397A (en) | 2019-03-28 |
CN113999281A (en) | 2022-02-01 |
MX2021002588A (en) | 2021-04-19 |
CN108697701B (en) | 2021-10-26 |
US11555054B2 (en) | 2023-01-17 |
US20190031716A1 (en) | 2019-01-31 |
ES2837484T3 (en) | 2021-06-30 |
WO2017136717A1 (en) | 2017-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017214557B2 (en) | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof | |
ES2623287T3 (en) | Highly active nucleoside derivative for HCV treatment | |
US9085599B2 (en) | 2′allene-substituted nucleoside derivatives | |
CN106661077B (en) | New compound of 4 '-thionucleosides and preparation method thereof, pharmaceutical composition and application | |
RU2640582C2 (en) | Derivatives of vitamine b6 nucleotides, acyclic nucleotides and acyclic nucleoside phosphonates | |
CN107250146A (en) | Substituted nucleosides, nucleotides and the like | |
WO2012158811A2 (en) | Purine monophosphate prodrugs for treatment of viral infections | |
KR20100091978A (en) | 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | |
KR20110115601A (en) | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | |
CN108409820A (en) | As 4 '-azidos of HCV rna replicon inhibitor, 3 '-fluorine-substituted nucleoside derivates | |
US20090274686A1 (en) | Nucleoside phosphonate derivatives | |
CN107427530A (en) | 2 N being modified that the β C of 2 ' deoxidations of β D, 2 ' α fluorine 2 ' for HCV therapy substitute6Substituted purine nucleotides | |
CN109689672A (en) | 2 '-- N replaced for RNA virus treatment6The purine nucleotides replaced | |
US20160016986A1 (en) | Stabilized nucleotides for medical treatment | |
CA2912684A1 (en) | 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives | |
JP2021521210A (en) | A prodrug of deoxynucleosides for the treatment of diseases caused by an imbalanced nucleotide pool | |
BR112016008934B1 (en) | MUTUAL PRODRUG COMPRISING SHORT CHAIN FATTY ACIDS AND ZEBULARIN OR 1- CYANO-CYTARABINE FOR TREATMENT OF CANCER, AND USE OF SAID PRODRUG | |
KR20100053544A (en) | 5'-substituted adenosines, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase | |
US8642572B2 (en) | Cytidine derivative-containing antitumor agent for continuous intravenous administration | |
Yue et al. | Research Progress on hCNT3 Structure/Function and Nucleoside Anticancer Drugs | |
AU2022339679A1 (en) | 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment | |
WO2023034617A1 (en) | 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment | |
TW202140018A (en) | Antitumor effect enhancing agent containing uracil derivative compound | |
SG189699A1 (en) | Anti-tumor agent comprising cytidine derivative and carboplatin | |
WO2016195353A1 (en) | A use of 1'-cyano-cytarabine for cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |